SOPHiA GENETICS CMO sells 5,000 shares in planned trade

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares at a weighted average price of $4.9548 per share.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares at a weighted average price of $4.9548 per share. The transaction was executed on May 26, 2026 pursuant to a duly adopted Rule 10b5-1(c) trading plan.

After this sale, Menu directly holds 250,780 Ordinary Shares, indicating he retains a substantial equity position in the company. The sale price reflects multiple trades within a range of $4.78 to $5.01 per share, aggregated into the reported weighted average.

Insights

Equity markets & insider transactions analyst

Small, pre-planned insider sale with large remaining holdings.

The Chief Medical Officer sold 5,000 SOPHiA GENETICS Ordinary Shares in an open-market transaction at a weighted average of $4.9548 per share on May 26, 2026. This is categorized as a straightforward sale of common equity.

The filing shows the sale was made under a duly adopted Rule 10b5-1(c) trading plan, meaning it was pre-scheduled rather than timed discretionarily. Following the sale, the insider still directly holds 250,780 shares, suggesting this is a relatively small portfolio adjustment rather than a major position change.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Menu Philippe

Role Chief Medical Officer

Sold 5,000 shs ($25K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	5,000	$4.9548	$25K

Holdings After Transaction: Ordinary Shares — 250,780 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.78 to $5.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 5,000 shares Weighted average sale price: $4.9548 per share Shares held after transaction: 250,780 shares +2 more

5 metrics

Shares sold 5,000 shares Open-market sale of Ordinary Shares on May 26, 2026

Weighted average sale price $4.9548 per share Aggregate price across multiple trades ranging from $4.78 to $5.01

Shares held after transaction 250,780 shares Direct holdings of Philippe Menu after the sale

Price range of trades $4.78–$5.01 per share Range of individual trade prices underlying the weighted average

Transaction code S (sale in open market or private transaction) Indicates nature of insider transaction

Key Terms

Rule 10b5-1(c), weighted average price, open-market sale, Ordinary Shares, +1 more

5 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

""security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

transaction code "S" regulatory

""transaction_code": "S""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOPHiA GENETICS (SOPH) report for Philippe Menu?

SOPHiA GENETICS reported that Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares. The sale occurred on May 26, 2026, as an open-market transaction at a weighted average price of $4.9548 per share, according to the Form 4 disclosure.

At what price did Philippe Menu sell SOPH shares in this Form 4?

The reported sale used a weighted average price of $4.9548 per share. Footnotes explain the shares were sold in multiple trades with prices ranging from $4.78 to $5.01, and detailed trade information is available on written request.

How many SOPHiA GENETICS shares does Philippe Menu hold after the reported sale?

After the transaction, Philippe Menu directly holds 250,780 Ordinary Shares of SOPHiA GENETICS. This post-transaction holding, disclosed in the Form 4, indicates he retains a significant equity interest despite the relatively small sale.

Was the SOPH insider sale by Philippe Menu under a Rule 10b5-1 trading plan?

Yes. A footnote states the transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Such plans pre-schedule trades, reducing the significance of trade timing as a signal of the insider’s short-term market view.

What type of transaction is reported in the SOPH Form 4 for Philippe Menu?

The Form 4 shows an open-market sale of non-derivative securities, specifically Ordinary Shares. The transaction code is “S,” described as a sale in open market or private transaction, confirming it was a straightforward share disposition rather than an option exercise or gift.

How many SOPHiA GENETICS shares did Philippe Menu sell in total?

He sold a total of 5,000 Ordinary Shares. While these were executed across multiple trades within a price range of $4.78 to $5.01, the filing aggregates them into a single reported amount and weighted average sale price of $4.9548 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 07:38 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/26/2026		S		5,000(1)	D	$4.9548(2)	250,780	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.78 to $5.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)